GSK touts Arexvy sales as it dom­i­nates US old­er adult RSV mar­ket, com­pa­ny cuts three ear­ly-stage as­sets

GSK’s RSV vac­cine Arexvy got off to a strong start in its first full quar­ter post-launch, the com­pa­ny re­vealed dur­ing its third-quar­ter earn­ings. It al­so an­nounced it was trim­ming three ear­ly-stage as­sets from its pipeline.

GSK’s to­tal Q3 sales grew by 10% to £8.1 bil­lion ($9.84 bil­lion). Vac­cine per­for­mance as a whole was es­pe­cial­ly ro­bust, with sales to­tal­ing £3.22bn ($3.9 bil­lion). Arexvy made £700 mil­lion ($850 mil­lion) in Q3 and cur­rent­ly ac­counts for two out of every three re­tail pre­scrip­tions for an RSV jab, with the rest made up of ri­val Pfiz­er’s Abrys­vo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER